Navigation Links
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Date:6/2/2008

ytarabine (Ara-C) to cytarabine alone.

A second phase 3 study of clofarabine sponsored by the Eastern Cooperative Oncology Group is expected to begin enrolling patients next year. This study will compare single agent clofarabine to conventional induction chemotherapy in untreated AML patients age 60 and older who are considered suitable for conventional induction chemotherapy.

Clolar is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory ALL after at least two prior regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted.

Genzyme also is actively exploring additional therapeutic indications for Clolar, including in MDS.

Genzyme Hosts Investor Call Tomorrow Morning

Genzyme will host an investor call tomorrow morning, Tuesday, June 3 at 10 a.m. EST. The preliminary data from the CLASSIC-II pivotal study will be reviewed and there will be opportunity for investors to ask questions of Genzyme.

To participate in the call, please dial 1-888-982-7287 in the U.S. or 1-210-234-0251 outside of the U.S. The participant passcode is "Genzyme."

A replay of this call will be available by dialing 1-800-695-3397. This call will also be available live on the investor events section of http://www.genzyme.com. Replays of the call will be available until 10:59 p.m. on June 10, 2008.

About Clolar

Clolar has Orphan Drug designation for adult and pediatric ALL, and seven years of market exclusivity in the United States for relapsed/refractory pediatric ALL. The FDA also granted six months of extended market exclusivity to Clolar under the Best Pharmaceuticals for Children Act.

Clolar should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... McGraw-Hill Education Professional, a leading global provider ... medical communities, has announced the launch of the ... the world-renowned medical education platform. A ... available for download onto all iOS and Android devices, ... access to valuable AccessMedicine diagnostic resources in ...
(Date:7/29/2014)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2014 financial results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1907 (US) or 785-424-1826 (International) ...
(Date:7/29/2014)... July 29, 2014 Research and Markets ... Respiratory Devices Market 2014-2018" report to their offering. ... A respiratory device is a medical device used to ... difficulty in breathing and cannot achieve adequate oxygen levels ... cystic fibrosis, asthma, COPD, and ARDS require the need ...
Breaking Medicine Technology:McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2Global Respiratory Devices Market 2014-2018 2
(Date:7/29/2014)... Hopkins researchers say they have discovered a chemical alteration ... that, if confirmed in larger studies, could give doctors ... risk of attempting suicide. , The discovery, described online ... that changes in a gene involved in the function ... significant role in turning what might otherwise be an ...
(Date:7/29/2014)... Diabetes is a common condition diagnosed in millions of people. ... while the production of insulin is decreased. , Insulin ... needed by the body to regulate blood sugar levels. Diabetes ... as there are numerous complications that can be developed by ... read a complex review of Matt Traverso's new book go ...
(Date:7/29/2014)... For numerous women from all over the world, ... out being quite hard. Well, the author of the Make ... that can help all these women. This is the formula ... love and attention every day. , Daily Gossip reveals ... by Alex Carter who published a unique eBook to detail ...
(Date:7/29/2014)... Daily Gossip writes in its Fibroids Miracle review that this ... users how to permanently eliminate uterine fibroids. The system has ... the world. , They have been able to get ... as 12 hours. This means that pain and other disturbing ... Fibroids Miracle review also indicates that the method was developed ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Want young children ... them something that,s healthy is good for them. Doing ... good, a new study suggests. "Parents and caregivers ... may be better off simply serving the food without ... yummy the food actually is," said study authors Michal ...
Breaking Medicine News(10 mins):Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:"Make Him Desire You" Review Reveals Unique Formula to Make Men Feel a Special Kind of Love 2Health News:Amanda Leto’s Fibroids Miracle Review Reveals Clinically Proven Uterine Fibroids Cure System 2Health News:Kids Will Pass on 'Healthy' Foods 2
... The Substance Abuse and,Mental Health Services Administration ... inaugural Science and Service Awards. These awards,recognize ... treat mental illnesses and substance abuse., ... to public sector,organizations and community-based groups and ...
... Collection Donates 100% of Net Profits to The ... Ovarian Cancer Research Fund, ... anniversary of its partnership with The Ovarian Cancer Research,Fund (OCRF) and ... decade, L,Oreal Paris has offered hope to the tens of,thousands of ...
... Sicko Serve as Reminder of Need for Genuine Reform -,Nurses ... ... International Nurses Panel Lauds Guaranteed Healthcare Systems, ... Michael Moore,s Sicko will lead a delegation of several,hundred registered ...
... the pharmacys name or logo rather than instructions on ... in the September 10 issue of the Archives of ... 1.5 million medication errors occur each year in the ... the mistakes. While the Food and Drug Administration has ...
... medications again, study finds , , TUESDAY, Sept. 11 (HealthDay ... chronic health problems such as high blood pressure and ... prescription drug plans, new research shows. , The ... also found that many of those seniors do not ...
... The Innovative Vector Control Consortium (IVCC) has embarked ... year strategy with the launch of the first ... health mosquito control products. The three projects, ... IVCC projects developing improved mosquito control information systems. ...
Cached Medicine News:Health News:SAMHSA Announces First Science and Service Award Winners 2Health News:SAMHSA Announces First Science and Service Award Winners 3Health News:SAMHSA Announces First Science and Service Award Winners 4Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 2Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 3Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 4Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 5Health News:September 11th First Responders Lead Emotional Rally at State Capitol Tuesday 2Health News:Prescription labels geared toward pharmacies, not patients 2Health News:Medicare Spending Caps Cause Seniors to Stop Meds 2Health News:IVCC launches groundbreaking insecticide projects with Bayer and Syngenta 2
... dedicated fluorometer from Berthold Technologies, has ... variety of measurement modes to support ... scanning, dual ratio measurements plus top ... valuable instrument for any researcher using ...
The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates....
... VISUCAM non-mydriatic fundus camera ... simplicity of fundus imaging. ... to set the standard ... features a unique combination ...
Small, compact and versatile, the CLK-4 light source is compatible with all Olympus fiberscopes and is ideal for the vast majority of routine fiber-endoscopic procedures, especially in the out-patien...
Medicine Products: